John David Imig, PhD

Full Member

Research Program:

Cancer Therapeutics

Faculty Rank:

Chair and Professor

Campus:

University of Arkansas for Medical Sciences

College:

College of Pharmacy

Department:

Pharmaceutical Sciences

Cancer Research Interest

Disease Site Focus: No Specific Disease Site
Research Focus Area: Treatment
Type of Research: Basic, Translational
Research Keywords: eicosanoids, cardiovascular, renal, nephrotoxicity, cardiotoxicity, drug development
Research Interest Statement: The Imig laboratory is dedicated to understanding how certain fatty acids, known as epoxylipids, influence kidney, metabolic, and cardiovascular function. His team has advanced its findings through translational research and developed new epoxylipid-based drugs to potentially treat diseases including heart attacks, stroke, diabetes, non-alcoholic fatty liver disese, and kidney diseases. These drugs have also been demonstrated to protect against radiation and anti-cancer drug related kidney and cardiovascular toxicities.

Contact Information

Email Address: JImig@uams.edu
Profiles Research Networking Software: View Profile

Publications

Imig JD, Abdul Hye Khan M, Stavniichuk A, [et al.]. Salt-Sensitive Hypertension after Reversal of Unilateral Ureteral Obstruction. Biochemical pharmacology. 2023:115438. PMID: 36716827.
Imig JD. Osteopontin Regulates Phosphate Solubility to Prevent Mineral Aggregates in CKD. Kidney360. 2022 3(9):1477-1479. PMID: 36245661. PMCID: PMC9528367.
Imig JD. SARS-CoV-2 spike protein causes cardiovascular disease independent of viral infection. Clinical science (London, England : 1979). 2022 136(6):431-434. PMID: 35348182. PMCID: PMC8965847.
Imig JD, Cervenka L, Neckar J. Epoxylipids and soluble epoxide hydrolase in heart diseases. Biochemical pharmacology. 2022 195:114866. PMID: 34863976. PMCID: PMC8712413.
Chiang KC, Rizk JG, Nelson DJ, [et al., including Imig JD]. Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath. Expert opinion on therapeutic targets. 2022 26(1):13-28. PMID: 35068281.
Imig JD, Zhao X, Elmarakby AA, Pavlov T. Editorial: Interactions Between Podocytes, Mesangial Cells, and Glomerular Endothelial Cells in Glomerular Diseases. Frontiers in physiology. 2022 13:849693. PMID: 35399279. PMCID: PMC8984182.
Imig JD. Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury. Advances in pharmacology (San Diego, Calif.). 2022 94:27-55. PMID: 35659375.
Chiang KC, Imig JD, Kalantar-Zadeh K, Gupta A. Kidney in the net of acute and long-haul coronavirus disease 2019: a potential role for lipid mediators in causing renal injury and fibrosis. Current opinion in nephrology and hypertension. 2022 31(1):36-46. PMID: 34846312.
Imig JD. Frontiers in metabolic physiology grand challenges. Frontiers in physiology. 2022 13:879617. PMID: 36035475. PMCID: PMC9399398.
Khan MAH, Hwang SH, Barnett SD, [et al., including Imig JD]. Multitarget molecule, PTUPB, to treat diabetic nephropathy in rats. British journal of pharmacology. 2021 178(22):4468-4484. PMID: 34255857. PMCID: PMC8863090.
Imig JD, Merk D, Proschak E. Multi-Target Drugs for Kidney Diseases. Kidney360. 2021 2(10):1645-1653. PMID: 35372984. PMCID: PMC8785794.
Widiapradja A, Kasparian AO, McCaffrey SL, [et al., including Imig JD]. Replacement of Lost Substance P Reduces Fibrosis in the Diabetic Heart by Preventing Adverse Fibroblast and Macrophage Phenotype Changes. Cells. 2021 10(10). PMID: 34685639. PMCID: PMC8534147.
Kala P, Miklovi? M, Jíchová ?, [et al., including Imig JD]. Effects of Epoxyeicosatrienoic Acid-Enhancing Therapy on the Course of Congestive Heart Failure in Angiotensin II-Dependent Rat Hypertension: From mRNA Analysis towards Functional In Vivo Evaluation. Biomedicines. 2021 9(8). PMID: 34440257. PMCID: PMC8393645.
Imig JD. Diabetes risk associated with plasma epoxylipid levels. EBioMedicine. 2021 66:103331. PMID: 33857907. PMCID: PMC8050865.
Imig JD, Hye Khan MA, Burkhan A, [et al.]. Kidney-Targeted Epoxyeicosatrienoic Acid Analog, EET-F01, Reduces Inflammation, Oxidative Stress, and Cisplatin-Induced Nephrotoxicity. International journal of molecular sciences. 2021 22(6). PMID: 33801911. PMCID: PMC7998941.
Klemens CA, Chulkov EG, Wu J, [et al., including Imig JD]. Loss of Chloride Channel 6 (CLC-6) Affects Vascular Smooth Muscle Contractility and Arterial Stiffness via Alterations to Golgi Calcium Stores. Hypertension (Dallas, Tex. : 1979). 2021 77(2):582-593. PMID: 33390052. PMCID: PMC7856014.
Jankiewicz WK, Barnett SD, Stavniichuk A, [et al., including Imig JD]. Dual sEH/COX-2 Inhibition Using PTUPB-A Promising Approach to Antiangiogenesis-Induced Nephrotoxicity. Frontiers in pharmacology. 2021 12:744776. PMID: 34955823. PMCID: PMC8695932.
Baranowska I, Gawrys O, Walkowska A, [et al., including Imig JD]. Epoxyeicosatrienoic Acid Analog and 20-HETE Antagonist Combination Prevent Hypertension Development in Spontaneously Hypertensive Rats. Frontiers in pharmacology. 2021 12:798642. PMID: 35111064. PMCID: PMC8802114.
Walkowska A, ?ervenka L, Imig JD, [et al.]. Early Renal Vasodilator and Hypotensive Action of Epoxyeicosatrienoic Acid Analog (EET-A) and 20-HETE Receptor Blocker (AAA) in Spontaneously Hypertensive Rats. Frontiers in physiology. 2021 12:622882. PMID: 33584348. PMCID: PMC7876274.
George J, Zhang Y, Sloan J, [et al., including Imig JD]. Tim-1 Deficiency Aggravates High-Fat Diet-Induced Steatohepatitis in Mice. Frontiers in immunology. 2021 12:747794. PMID: 34675931. PMCID: PMC8523998.
Maranto C, Udhane V, Jia J, [et al., including Imig JD]. Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. Cancers. 2020 12(11). PMID: 33217941. PMCID: PMC7724566.
Imig JD. Eicosanoid blood vessel regulation in physiological and pathological states. Clinical science (London, England : 1979). 2020 134(20):2707-2727. PMID: 33095237.
Stavniichuk A, Hye Khan MA, Yeboah MM, [et al., including Imig JD]. Dual soluble epoxide hydrolase inhibitor/PPAR-? agonist attenuates renal fibrosis. Prostaglandins & other lipid mediators. 2020 150:106472. PMID: 32569747.
Gawrys O, Husková Z, Baranowska I, [et al., including Imig JD]. Combined treatment with epoxyeicosatrienoic acid analog and 20-hydroxyeicosatetraenoic acid antagonist provides substantial hypotensive effect in spontaneously hypertensive rats. Journal of hypertension. 2020 38(9):1802-1810. PMID: 32384390.
Imig JD, Jankiewicz WK, Khan AH. Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture. Hypertension (Dallas, Tex. : 1979). 2020 76(1):3-15. PMID: 32475311. PMCID: PMC7448548.
Stavniichuk A, Savchuk O, Khan AH, [et al., including Imig JD]. THE EFFECT OF COMPOUND DM509 ON KIDNEY FIBROSIS IN THE CONDITIONS OF THE EXPERIMENTAL MODEL. Visnyk Kyivs'koho natsional'noho universytetu imeni Tarasa Shevchenka. Biolohiia. 2020 80(1):10-15. PMID: 33437972. PMCID: PMC7799440.
Stavniichuk A, Savchuk O, Khan AH, [et al., including Imig JD]. A SORAFENIB INDUCED MODEL OF GLOMERULAR KIDNEY DISEASE. Visnyk Kyivs'koho natsional'noho universytetu imeni Tarasa Shevchenka. Biolohiia. 2020 81(2):25-31. PMID: 33251532. PMCID: PMC7696638.
Imig JD, Hye Khan MA, Zhao X. Editorial: Renal Function in Acute and Chronic Kidney Diseases. Frontiers in physiology. 2020 11:625353. PMID: 33343402. PMCID: PMC7744816.
Lillich FF, Imig JD, Proschak E. Multi-Target Approaches in Metabolic Syndrome. Frontiers in pharmacology. 2020 11:554961. PMID: 33776749. PMCID: PMC7994619.
Imig JD, Morisseau C. Editorial: Clinical Paths for Soluble Epoxide Hydrolase Inhibitors. Frontiers in pharmacology. 2020 11:598858. PMID: 33071800. PMCID: PMC7544929.
Imig JD. Epoxyeicosanoids in hypertension. Physiological research. 2019 68(5):695-704. PMID: 31475560. PMCID: PMC6941753.
Hye Khan MA, Schmidt J, Stavniichuk A, [et al., including Imig JD]. A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice. Biochemical pharmacology. 2019 166:212-221. PMID: 31129048. PMCID: PMC6939295.
Widiapradja A, Manteufel EJ, Dehlin HM, [et al., including Imig JD]. Regulation of Cardiac Mast Cell Maturation and Function by the Neurokinin-1 Receptor in the Fibrotic Heart. Scientific reports. 2019 9(1):11004. PMID: 31358823. PMCID: PMC6662794.
Necká? J, Hye Khan MA, Gross GJ, [et al., including Imig JD]. Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats. Clinical science (London, England : 1979). 2019 133(8):939-951. PMID: 30979784. PMCID: PMC6492034.
?ertíková Chábová V, Kujal P, Va?ourková Z, [et al., including Imig J]. Addition of Endothelin A-Receptor Blockade Spoils the Beneficial Effect of Combined Renin-Angiotensin and Soluble Epoxide Hydrolase Inhibition: Studies on the Course of Chronic Kidney Disease in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats. Kidney & blood pressure research. 2019 44(6):1493-1505. PMID: 31770762.
Vacková ?, Kikerlová S, Melenovsky V, [et al., including Imig JD]. Altered Renal Vascular Responsiveness to Vasoactive Agents in Rats with Angiotensin II-Dependent Hypertension and Congestive Heart Failure. Kidney & blood pressure research. 2019 44(4):792-809. PMID: 31430751.
Hye Khan MA, Stavniichuk A, Sattar MA, [et al., including Imig JD]. Epoxyeicosatrienoic Acid Analog EET-A Blunts Development of Lupus Nephritis in Mice. Frontiers in pharmacology. 2019 10:512. PMID: 31133860. PMCID: PMC6523399.
Hrdli?ka J, Necká? J, Papou?ek F, [et al., including Imig JD]. Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats. Frontiers in pharmacology. 2019 10:159. PMID: 30881303. PMCID: PMC6406051.
Vacková ?, Kopkan L, Kikerlová S, [et al., including Imig JD]. Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats. Frontiers in pharmacology. 2019 10:18. PMID: 30728778. PMCID: PMC6351500.
Imig JD. Epigenetic soluble epoxide hydrolase regulation causes endothelial dysfunction. Acta physiologica (Oxford, England). 2019 225(1):e13203. PMID: 30307705. PMCID: PMC6548442.
Imig JD. Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics. Pharmacology & therapeutics. 2018 192:1-19. PMID: 29964123. PMCID: PMC6263841.
Miller BS, Blumenthal SR, Shalygin A, [et al., including Imig JD]. Inactivation of p66Shc Decreases Afferent Arteriolar KATP Channel Activity and Decreases Renal Damage in Diabetic Dahl SS Rats. Diabetes. 2018 67(11):2206-2212. PMID: 30131395. PMCID: PMC6198347.
Necká? J, Hsu A, Hye Khan MA, [et al., including Imig JD]. Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1? via downregulation of prolyl hydroxylase 3. American journal of physiology. Heart and circulatory physiology. 2018 315(5):H1148-H1158. PMID: 30074840. PMCID: PMC6734065.
Sedláková L, Kikerlová S, Husková Z, [et al., including Imig JD]. 20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats. Bioscience reports. 2018 38(5). PMID: 30054426. PMCID: PMC6131326.
Hye Khan MA, Kolb L, Skibba M, [et al., including Imig JD]. A novel dual PPAR-? agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes. Diabetologia. 2018 61(10):2235-2246. PMID: 30032428. PMCID: PMC6563928.
Yeboah MM, Hye Khan MA, Chesnik MA, [et al., including Imig JD]. Role of the cytochrome P-450/ epoxyeicosatrienoic acids pathway in the pathogenesis of renal dysfunction in cirrhosis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2018 33(8):1333-1343. PMID: 29361048. PMCID: PMC6070028.
Kala P, Sedláková L, ?karoupková P, [et al., including Imig JD]. Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula. Physiological research. 2018 67(3):401-415. PMID: 29527914. PMCID: PMC6056335.
?ervenka L, Husková Z, Kopkan L, [et al., including Imig JD]. Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension. Journal of hypertension. 2018 36(6):1326-1341. PMID: 29570510. PMCID: PMC7375140.
?ertíková Chábová V, Kujal P, ?karoupková P, [et al., including Imig JD]. Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease. Kidney & blood pressure research. 2018 43(2):329-349. PMID: 29529602. PMCID: PMC5985203.
Bettaieb A, Koike S, Hsu MF, [et al., including Imig JD]. Soluble epoxide hydrolase in podocytes is a significant contributor to renal function under hyperglycemia. Biochimica et biophysica acta. General subjects. 2017 1861(11 Pt A):2758-2765. PMID: 28757338. PMCID: PMC5873293.
Campbell WB, Imig JD, Schmitz JM, Falck JR. Orally Active Epoxyeicosatrienoic Acid Analogs. Journal of cardiovascular pharmacology. 2017 70(4):211-224. PMID: 28937442. PMCID: PMC5673125.
Gangadhariah MH, Dieckmann BW, Lantier L, [et al., including Imig JD]. Cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids contribute to insulin sensitivity in mice and in humans. Diabetologia. 2017 60(6):1066-1075. PMID: 28352940. PMCID: PMC5921930.
Skibba M, Hye Khan MA, Kolb LL, [et al., including Imig JD]. Epoxyeicosatrienoic Acid Analog Decreases Renal Fibrosis by Reducing Epithelial-to-Mesenchymal Transition. Frontiers in pharmacology. 2017 8:406. PMID: 28713267. PMCID: PMC5491687.
Jíchová ?, Kopkan L, Husková Z, [et al., including Imig JD]. Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats. Journal of hypertension. 2016 34(10):2008-25. PMID: 27428043. PMCID: PMC5510029.
Hye Khan MA, Hwang SH, Sharma A, [et al., including Imig JD]. A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat. Prostaglandins & other lipid mediators. 2016 125:40-7. PMID: 27432695. PMCID: PMC5035206.
Yeboah MM, Hye Khan MA, Chesnik MA, [et al., including Imig JD]. The epoxyeicosatrienoic acid analog PVPA ameliorates cyclosporine-induced hypertension and renal injury in rats. American journal of physiology. Renal physiology. 2016 311(3):F576-85. PMID: 27358055. PMCID: PMC5504406.
Miller B, Palygin O, Rufanova VA, [et al., including Imig JD]. p66Shc regulates renal vascular tone in hypertension-induced nephropathy. The Journal of clinical investigation. 2016 126(7):2533-46. PMID: 27270176. PMCID: PMC4922697.
Imig JD, Hye Khan MA, Sharma A, [et al.]. Radiation-induced afferent arteriolar endothelial-dependent dysfunction involves decreased epoxygenase metabolites. American journal of physiology. Heart and circulatory physiology. 2016 310(11):H1695-701. PMID: 27106038. PMCID: PMC4935507.
Sharma A, Hye Khan MA, Levick SP, [et al., including Imig JD]. Novel Omega-3 Fatty Acid Epoxygenase Metabolite Reduces Kidney Fibrosis. International journal of molecular sciences. 2016 17(5). PMID: 27213332. PMCID: PMC4881572.
Imig JD. Renal blood flow autoregulation: what are the contributions for nitric oxide or superoxide to modulate the myogenic response?. American journal of physiology. Renal physiology. 2016 310(10):F1013-5. PMID: 26962100. PMCID: PMC5002057.
Sporková A, Reddy RN, Falck JR, [et al., including Imig JD]. Interlobular Arteries From 2-Kidney, 1-Clip Goldblatt Hypertensive Rats' Exhibit-Impaired Vasodilator Response to Epoxyeicosatrienoic Acids. The American journal of the medical sciences. 2016 351(5):513-9. PMID: 27140711. PMCID: PMC5021442.